These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16840202)

  • 1. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma.
    Zojer N; Kirchbacher K; Vesely M; Hübl W; Ludwig H
    Leuk Lymphoma; 2006 Jun; 47(6):1103-9. PubMed ID: 16840202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
    Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
    Treon SP; Pilarski LM; Belch AR; Kelliher A; Preffer FI; Shima Y; Mitsiades CS; Mitsiades NS; Szczepek AJ; Ellman L; Harmon D; Grossbard ML; Anderson KC
    J Immunother; 2002; 25(1):72-81. PubMed ID: 11924912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.
    Baz R; Fanning S; Kunkel L; Gaballa S; Karam MA; Reed J; Kelly M; Hussein M
    Leuk Lymphoma; 2007 Dec; 48(12):2338-44. PubMed ID: 18067008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
    Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
    Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term response to maintenance treatment with rituximab in CD20(+) multiple myeloma.
    Ohno H
    Leuk Lymphoma; 2010 Nov; 51(11):2144-6. PubMed ID: 20807088
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al.
    Greipp PT; Kapoor P; Morice WG; Witzig TE; Greipp PR
    Leukemia; 2008 Jan; 22(1):214-5. PubMed ID: 17928885
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-CD20 monoclonal antibody therapy in multiple myeloma.
    Kapoor P; Greipp PT; Morice WG; Rajkumar SV; Witzig TE; Greipp PR
    Br J Haematol; 2008 Apr; 141(2):135-48. PubMed ID: 18318769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma.
    Hofer S; Hunziker S; Dirnhofer S; Ludwig C
    Br J Haematol; 2003 Aug; 122(4):690-1. PubMed ID: 12899729
    [No Abstract]   [Full Text] [Related]  

  • 12. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy.
    Korte W; Jost C; Cogliatti S; Hess U; Cerny T
    Ann Oncol; 1999 Oct; 10(10):1249-50. PubMed ID: 10586345
    [No Abstract]   [Full Text] [Related]  

  • 13. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.
    Perz J; Topaly J; Fruehauf S; Hensel M; Ho AD
    Leuk Lymphoma; 2002 Jan; 43(1):149-51. PubMed ID: 11908720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in CD20 positive multiple myeloma.
    Moreau P; Voillat L; Benboukher L; Mathiot C; Dumontet C; Robillard N; Hérault O; Garnache F; Garand R; Varoqueaux N; Avet-Loiseau H; Harousseau JL; Bataille R;
    Leukemia; 2007 Apr; 21(4):835-6. PubMed ID: 17268523
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
    Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
    Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.
    Treon SP; Anderson KC
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):79-85. PubMed ID: 11226004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.
    Aklilu M; Stadler WM; Markiewicz M; Vogelzang NJ; Mahowald M; Johnson M; Gajewski TF
    Ann Oncol; 2004 Jul; 15(7):1109-14. PubMed ID: 15205206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Loss of CD20 expression following rituximab-combined chemotherapy in CD20-positive and CyclinD1-positive multiple myeloma].
    Shiratori S; Kondo T; Kubota K; Wakasa K; Ibata M; Shono Y; Takahata M; Shigematu A; Kato N; Ota S; Tanaka J; Matsuno Y; Asaka M; Imamura M
    Rinsho Ketsueki; 2008 Nov; 49(11):1536-40. PubMed ID: 19047784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.